# The RESET System Pivotal Clinical Trial (Protocol Revision K)

Study · id `cardio:ct-nct04101669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04101669](<https://clinicaltrials.gov/study/NCT04101669>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04101669

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.

## Technical summary

Registry record NCT04101669. Randomized; triple masking; primary purpose treatment. Start 2019-09-09 (actual); primary completion 2027-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 264 participants (planned count; ClinicalTrials.gov record NCT04101669, source copy `cardio:ctgov-nct04101669-2026-10-13`, retrieved 2026-10-26)
- Started: 2019-09-09 (actual) (ClinicalTrials.gov record NCT04101669, source copy `cardio:ctgov-nct04101669-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT04101669, source copy `cardio:ctgov-nct04101669-2026-10-13`, retrieved 2026-10-26)
- Completion: 2029-09-30 (anticipated) (ClinicalTrials.gov record NCT04101669, source copy `cardio:ctgov-nct04101669-2026-10-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04101669, source copy `cardio:ctgov-nct04101669-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04101669-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: The RESET System Pivotal Clinical Trial (Protocol Revision K)
- Acronym: STEP-1
- Condition: Diabetes type2
- Condition: Obesity
- Intervention (Device): RESET Liner
- Intervention (Other): Sham
- Lead sponsor: Morphic Medical Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Biostatistical Consulting, Inc.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 4b5c3be76fa645f73c30733bdd75f691a0c01d69369466d67ec56c6a020eb8d4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
